RSA Recognized in 2024 Gartner® Magic Quadrant™ for Access Management
RSA, the security-first identity leader, announced today that RSA® ID Plus, the world’s most secure identity and access management (IAM) platform has been named a Niche Player in the 2024 Gartner® Magic Quadrant™ for Access Management.
With only ten organizations named to the Gartner report, RSA believes that the Magic Quadrant signals the world’s top IAM vendors. ID Plus brings comprehensive identity protection to some of the world’s most security-sensitive organizations across banking, securities, insurance, and government. Available as SaaS, on-premises, or in hybrid configurations, ID Plus offers organizations flexibility in deployment and specialization in high-security workforce environments. Through various subscription models featuring a range of editions and add-ons, ID Plus meets diverse needs, supporting the evolving workforce requirements and regulatory landscapes throughout North America, South America, Europe, and the Asia-Pacific markets.
RSA believes that several capabilities and strengths contributed to ID Plus being listed in the 2024 Gartner Magic Quadrant for Access Management, including:
- High customer satisfaction and retention
- Specialization in workforce use cases, particularly for high-security verticals
- Broad support for cloud, hybrid, and on-premises environments
- A high-availability, high-security failover process that ensures uninterrupted access even during cloud outages
- Integrations with existing data and applications that enable buyers to maintain local configurations
“For decades, RSA has set the standard in secure authentication, but our story goes far beyond that. Seeing ID Plus break into the 2024 Gartner Magic Quadrant for Access Management and being recognized as a workforce security specialist, we feel, highlights the work we’ve done to develop a unified identity platform capable of securing the entire identity lifecycle and protecting highly regulated industries,” said RSA CEO Rohit Ghai.
“We feel that being named to the Gartner Magic Quadrant establishes RSA as one of the world’s top ten IAM vendors, and we’re not planning on going anywhere,” said RSA Chief Product and Technology Officer Jim Taylor, who detailed why workforce access management challenges organizations, how RSA supports customer access management, and the organization's access management roadmap in a new blog post. “Workforce access management is hard because it demands balancing security, usability, and scalability without getting any component wrong. I’d rather RSA be known as a workforce security specialist than an access generalist: that’s always been where RSA delivers the most value and what our customers need. With hundreds of IAM vendors worldwide, this recognition validates our commitment to delivering the full range of access, authentication, governance, and lifecycle capabilities that every organization requires.”
“While we may be new to the Magic Quadrant, security-first industries have relied on our access management solutions for years,” said RSA President and Chief Business Officer Greg Nelson. “Security-first leaders in government, finance, energy, and other regulated industries have long trusted RSA to deliver robust identity security solutions. We believe this recognition from Gartner underscores the strength of our strategy and reinforces our commitment to lead across every component of identity.”
Recent enhancements to ID Plus—including expanded identity insights, Bring Your Own Identity (BYOI) options, and OAuth 2.0 capabilities supporting machine-to-machine and IoT access—will bring further workforce security depth to the solution. RSA will introduce mobile passkey functionality, advanced directory enhancements, and increased AI and machine learning capabilities to assist security administrators in mitigating evolving threats.
RSA will showcase these innovations at the Gartner Identity & Access Management Summit from December 9-11 in Grapevine, Texas. Attendees are invited to visit RSA at booth 633 to experience demonstrations of the latest passwordless authentication and identity governance and administration (IGA) advancements. Book your demo with RSA at the Gartner IAM Summit now.
Resources
Read Jim Taylor’s blog post
Book your demo with RSA at the Gartner Identity & Access Management Summit
Start your free, 45-day trial of RSA ID Plus today
About RSA
The AI-powered RSA Unified Identity Platform protects the world’s most secure organizations from today’s and tomorrow’s highest-risk cyberattacks. RSA provides the identity intelligence, authentication, access, governance, and lifecycle capabilities needed to prevent threats, secure access, and enable compliance. More than 9,000 security-first organizations trust RSA to manage more than 60 million identities across on-premises, hybrid, and multi-cloud environments. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205057055/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom